Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
CNTX Context Therapeutics
0.700-0.027-3.71%
Close
01/27 16:00 ET
0.691-0.009-1.29%
Post Mkt Price 01/27 18:53 ET
High
0.730
Open
0.718
Turnover
76.95K
Low
0.691
Pre Close
0.727
Volume
108.81K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Context Therapeutics Says On Jan. 24 Co. Received Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard From Nasdaq
Context Therapeutics Says On Jan. 24 Co. Received Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard From Nasdaq
Context Therapeutics And 3 Other Stocks Under $1 Insiders Are Aggressively Buying
The Dow Jones closed higher by more than 250 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders int
Context Therapeutics Inc. (NASDAQ:CNTX) Short Interest Update
Context Therapeutics Inc. (NASDAQ:CNTX – Get Rating) was the target of a significant drop in short interest in the month of December. As of December 30th, there was short interest totalling 78,000 sh
Myomo, Enzo Biochem And These 2 Stocks Under $2 Insiders Are Aggressively Buying
The Dow Jones closed lower by more than 600 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders i
Context Therapeutics, Lonza Sign Manufacturing Deal for Cancer Drug Candidate
12:19 PM EST, 01/09/2023 (MT Newswires) -- Context Therapeutics (CNTX) and Lonza said Monday they have entered into a collaboration project to produce Context's clinical development candidate CTIM-76
Context Therapeutics Shares Rise 15% After Lonza Manufacturing Pact
By Chris Wack Context Therapeutics Inc. shares were up 15%, to 90 cents, on Monday after the Philadelphia biotechnology company said that it is collaborating with Lonza to make CTIM-76, its Claudin 6
Context Therapeutics Enters CTIM-76 Manufacturing Agreement With Lonza
By Chris Wack Context Therapeutics Inc. said Monday that it is collaborating with Lonza to make CTIM-76, its Claudin 6 and CD3 T-cell antibody targeting CLDN6 positive tumors. The companies said tha
Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers
Lonza to support the development and manufacturing of CTIM-76, Context's CLDN6 x CD3 bispecific antibody clinical candidate The bispecific antibody-based therapy is being developed to redirect T-cell mediated lysis
Context Therapeutics Provides Year-end Updates
Context Therapeutics Highlights 2023 Corporate Priorities And Pipeline Milestones; Co. Announces 'ELONA Breast Cancer Trial Open and Enrolled First Patient'
Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company developing novel treatments for solid tumors, with a primary focus on female cancers, t
Company Overview
More
Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The firm's robust clinical program for candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. Its ONA-XR is a novel, first-in-class small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women?s cancers. The company was founded by Martin Lehr and Felix Kim in April 2015 and is headquartered in Philadelphia, PA.
CEO： Mr. Martin Lehr
Market： NASDAQ
Listing Date： 10/20/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet